These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34395120)

  • 1. Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis.
    Verma N; Jaffer M; Pina Y; Peguero E; Mokhtari S
    Cureus; 2021 Jul; 13(7):e16337. PubMed ID: 34395120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management.
    Yanase T; Moritoki Y; Kondo H; Ueyama D; Akita H; Yasui T
    Urol Case Rep; 2021 Jan; 34():101508. PubMed ID: 33318935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in Refractory Myositis and Acute Neuropathy Secondary to Checkpoint Inhibitor Therapy.
    Jain V; Remley W; Bunag C; Elfasi A; Chuquilin M
    Cureus; 2022 May; 14(5):e25129. PubMed ID: 35733495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.
    Chen JH; Lee KY; Hu CJ; Chung CC
    Medicine (Baltimore); 2017 Dec; 96(50):e9262. PubMed ID: 29390370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis.
    Mangla A; Lee C; Mirsky MM; Wang M; Rothermel LD; Hoehn R; Bordeaux JS; Carroll BT; Theuner J; Li S; Fu P; Kirkwood JM
    JAMA Oncol; 2024 May; 10(5):612-620. PubMed ID: 38546551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report.
    Chen YH; Liu FC; Hsu CH; Chian CF
    Medicine (Baltimore); 2017 Jul; 96(27):e7350. PubMed ID: 28682883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
    Makarious D; Horwood K; Coward JIG
    Eur J Cancer; 2017 Sep; 82():128-136. PubMed ID: 28666240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of myasthenia gravis and myositis induced by nivolumab].
    Konoeda F; Suzuki S; Nishimoto Y; Hoshino H; Takagi M
    Rinsho Shinkeigaku; 2017 Jul; 57(7):373-377. PubMed ID: 28674287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
    Janssen JC; van Dijk B; de Joode K; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van den Eertwegh AJM; de Groot JWB; Jalving M; de Jonge MJA; Joosse A; Kapiteijn E; Kamphuis-Huismans AM; Naipal KAT; Piersma D; Rikhof B; Westgeest HM; Vreugdenhil G; Oomen-de Hoop E; Mulder EEAP; van der Veldt AAM
    BMC Cancer; 2024 May; 24(1):632. PubMed ID: 38783238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report.
    Saishu Y; Yoshida T; Seino Y; Nomura T
    J Med Case Rep; 2022 Feb; 16(1):61. PubMed ID: 35152911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report.
    Takada R; Fujiwara M; Maki M; Nomura N; Kono S; Fujita A; Masumoto H; Takahashi Y; Hasegawa Y; Tamura K
    J Pharm Health Care Sci; 2024 May; 10(1):26. PubMed ID: 38822426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
    Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
    J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab-Induced Ocular Myasthenic Crisis.
    Lorenzo CJ; Fitzpatrick H; Campdesuner V; George J; Lattanzio N
    Cureus; 2020 Jul; 12(7):e9192. PubMed ID: 32685327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis.
    Xing P; Zhang F; Wang G; Xu Y; Li C; Wang S; Guo Y; Cai S; Wang Y; Li J
    J Immunother Cancer; 2019 Dec; 7(1):341. PubMed ID: 31801636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
    Chapman PB; Jayaprakasam VS; Panageas KS; Callahan M; Postow MA; Shoushtari AN; Wolchok JD; Betof Warner A
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34702752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant development of neurologic and cardiac immune-related adverse effects in patients treated with immune checkpoint inhibitors for melanoma.
    Diamantopoulos PT; Tsatsou K; Benopoulou O; Bonou M; Anastasopoulou A; Mastrogianni E; Gogas H
    Melanoma Res; 2020 Oct; 30(5):484-491. PubMed ID: 32898389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment.
    Bir Yucel K; Sutcuoglu O; Yazıcı O; Yıldız Y; Şenol E; Uner A
    J Oncol Pharm Pract; 2023 Apr; 29(3):760-763. PubMed ID: 35938177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.